Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (539)	1/16/1998 10:35:00 AM
From: Henry Niman	Read Replies (1) \| Respond to of 1686

Have you seen an electronic version of the Analyst's wrap yet? I'm not surpised that van den Broek still likes LGND. He mentioned them last year in the wrap session and introduced them this year, saying that some analysts like platform comapnies and others like product companies, but LGND was easy to like since they had both. Last year he predicted that LGND would be the first profitable "targetted drug design" company, and the most recent Bear Stearns' report on LGND suggests that he will be correct (they project a 4Q profit this year and a year end profit for 1999).